Simcere Pharmaceutical Group (SMHGF) reported a profit for its full year that Increased, from last year
The company's bottom line totaled RMB1.344 billion, or RMB0.54 per share. This compares with RMB722.00 million, or RMB0.29 per share, last year.
The company's revenue for the period rose 16.5% to RMB7.731 billion from RMB6.635 billion last year.
Simcere Pharmaceutical Group earnings at a glance (GAAP) :
-Earnings: RMB1.344 Bln. vs. RMB722.00 Mln. last year.-EPS: RMB0.54 vs. RMB0.29 last year.-Revenue: RMB7.731 Bln vs. RMB6.635 Bln last year.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.